STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Tango Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Farallon-affiliated funds and related individuals filed an amended Schedule 13G reporting material passive holdings of Tango Therapeutics common stock. Farallon Partners, L.L.C. is shown as beneficial owner of 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons are shown with a collective 9,157,000 shares (8.4%). Several underlying Farallon funds report individual holdings, including Farallon Capital Offshore Investors II with 3,754,671 shares (3.5%) and Farallon Capital Institutional Partners with 2,023,027 shares (1.9%).

The filing states the shares are held directly by the named funds and that the general partner entities and listed individuals could be deemed beneficial owners while disavowing beneficial ownership of those shares. The Schedule is a passive disclosure of ownership and includes a certification that the securities were not acquired to effect a change of control.

Positive
  • Material institutional ownership disclosed: Farallon entities report substantial positions, including 8.1% (Farallon Partners) and 8.4% (aggregate individuals).
  • Passive disclosure and certification: The filing is a Schedule 13G/A and includes a certification that the securities were not acquired to effect a change of control.
Negative
  • No sole voting or dispositive power reported for any reporting person; all reported power is shared (sole power rows show 0).
  • Group status ambiguous: the Reporting Persons state they "neither disclaim nor affirm" the existence of a group, leaving potential coordination unclear.

Insights

TL;DR Farallon entities report an >8% stake in TNGX, a material institutional holding but disclosed as passive.

This Schedule 13G/A shows concentrated institutional exposure by Farallon-related funds and named principals to Tango Therapeutics common stock. Key figures are 8.1% (Farallon Partners, L.L.C.) and 8.4% (aggregate reported by the Individual Reporting Persons). The positions are reported as shared voting and dispositive power with no sole voting or sole dispositive power indicated for any reporting person. The filing also disclaims affirmative statements about a group while acknowledging potential deemed beneficial ownership through governance roles. For investors, this is material ownership information but presented as passive.

TL;DR Material institutional ownership disclosed with disclaimers about group status and beneficial ownership—governance implications possible but not asserted.

The filing identifies multiple Farallon funds and affiliated entities as holders of Tango common stock, and names 17 individual reporting persons tied to the Farallon General Partner. The document explicitly states that the General Partner and the named individuals "may be deemed" beneficial owners while simultaneously disclaiming beneficial ownership of the reported shares. The filers also note the holdings were not acquired to change control. The combination of concentrated holdings and the group-disclaimer language is a governance item investors may track, though the filing itself presents the position as passive.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025

FAQ

Who filed the Schedule 13G/A for Tango Therapeutics (TNGX)?

The filing was submitted by multiple Farallon-affiliated entities and individuals, collectively described as the "Reporting Persons," including Farallon Funds, Farallon Partners, L.L.C., and named Farallon individual reporting persons.

How many Tango Therapeutics shares do Farallon entities report owning?

Key reported amounts include Farallon Partners, L.L.C.: 8,798,334 shares (8.1%) and the Farallon Individual Reporting Persons aggregate: 9,157,000 shares (8.4%).

Are the Farallon filers reporting sole voting or dispositive power over TNGX shares?

No. The cover page rows indicate 0 sole voting power and 0 sole dispositive power for the reporting persons; the holdings are reported as shared voting and dispositive power.

Did the filers state an intent to change control of Tango Therapeutics (TNGX)?

No. The filing includes a certification stating the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Which individual Farallon reporting persons are named in the filing?

The filing names 17 individuals associated with Farallon General Partner roles, including Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, and others.

Does the filing clarify whether the Reporting Persons form a group?

The Reporting Persons state they are filing pursuant to the passive Schedule 13G provision and explicitly say they "neither disclaim nor affirm the existence of a group" among them.
Tango Therapeutics Inc

NASDAQ:TNGX

TNGX Rankings

TNGX Latest News

TNGX Latest SEC Filings

TNGX Stock Data

1.06B
126.97M
12.26%
109.5%
22.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON